Rationale and design of the pragmatic randomized trial of icosapent ethyl for high cardiovascular risk adults (MITIGATE)-Reference-Cited by-同舟云学术

Rationale and design of the pragmatic randomized trial of icosapent ethyl for high cardiovascular risk adults (MITIGATE)

Published:2021-05 Issue: Volume:235 Page:54-64
ISSN:0002-8703
Container-title:American Heart Journal
language:en
Short-container-title:American Heart Journal

Author:

Ambrosy Andrew P.,Malik Umar I.,Thomas Rachel C.,Parikh Rishi V.,Tan Thida C.,Goh Choon H.,Selby Van N.,Solomon Matthew D.,Avula Harshith R.,Fitzpatrick Jesse K.,Skarbinski Jacek,Philip Sephy,Granowitz Craig,Bhatt Deepak L.,Go Alan S.

Funder

National Institute of Diabetes and Digestive and Kidney Diseases

Novartis

National Institute on Aging

National Heart, Lung, and Blood Institute

Amarin Pharma

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference40 articles.

1. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study;Zhou;Lancet,2020

2. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy;Onder;JAMA,2020

3. Characteristics of hospitalized adults with COVID-19 in an integrated health care system in California;Myers;JAMA,2020

4. Rationale and design of REDUCE-IT: reduction of cardiovascular events with icosapent ethyl-intervention trial;Bhatt;Clin Cardiol,2017

5. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia;Bhatt;N Engl J Med,2019

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. High residual cardiovascular risk after lipid-lowering: prime time for Predictive, Preventive, Personalized, Participatory, and Psycho-cognitive medicine;Frontiers in Cardiovascular Medicine;2023-10-16

2. Icosapent ethyl (VASCEPA^®) as treatment for post-acute sequelae of SARS CoV-2 (PASC) vaccine induced injury and infection;Journal of Complementary and Integrative Medicine;2023-06-07

3. A Critical Review of Icosapent Ethyl in Cardiovascular Risk Reduction;American Journal of Cardiovascular Drugs;2023-05-15

4. Pneumonia-Induced Inflammation, Resolution and Cardiovascular Disease: Causes, Consequences and Clinical Opportunities;Circulation Research;2023-03-17

5. Omega-3 Polyunsaturated Fatty Acids (n-3 PUFAs) for Immunomodulation in COVID-19 Related Acute Respiratory Distress Syndrome (ARDS);Journal of Clinical Medicine;2022-12-30